Toggle light / dark theme

New tool maps cell types in lab-grown blobs of brain tissue

A new tool helps researchers explore the types of cells that make up brain organoids — clusters of cells that can mimic the basic structure, function and development of different parts of the brain.

The software, detailed in Cell Stem Cell, maps information about when and where genes are expressed in brain organoids onto a reference atlas of the developing mouse brain. Scientists can use the resulting overlay to develop organoids that better recapitulate the developing brain, the team says, or to uncover the effects of gene mutations and other experimental perturbations.

Brain organoids derived from the cells of people with conditions such as autism have proved useful in capturing neuronal abnormalities. But the findings are muddied by methodological differences in how researchers develop these lab-grown blobs. Advanced techniques to profile gene expression in single cells have made it easier to identify the cell types in any given organoid. But it’s remained difficult to map those cell types onto different brain regions.

How mutations in top autism gene could lead to seizures

Some mutations that disable SCN2A, one of the genes most strongly linked to autism, can unexpectedly make neurons hyperexcitable, a study in mice shows. The findings may help explain why a sizeable proportion of autistic children with mutations in SCN2A experience epileptic seizures.


Deleterious mutations in an autism-associated gene can make neurons hyperexcitable, raising the risk of epileptic seizures.

How To Improve On Our Thymus Health | Dr Greg Fahy Episode 5

A couple people from TRIM are in TRIM-X to see how it works a second time.


In this video Dr. Fahy discusses what we can do to make the most of our thymus without the growth hormone treatment, what the timing makes sense for rejuvenation of the thymus and whether the thymus is tied to the other hallmarks of aging.

Dr. Greg Fahy is a world renowned cryobiologist and is also the chief science officer, and co-founder, of Intervene Immune, a company which pioneers treatments for thymus regeneration and age-related immune system decline. Dr. Fahy Designed and led the pilot TRIIM trial which first time showing both thymus rejuvenation and reversal of human epigenetic age. He is now running the follow up phase II trial TRIIM-X with the aim of confirming and extending the results.

************************************************************
Health claims Disclosure: Information provided on this video is not a substitute for direct, individual medical treatment or advice. Please consult with your doctor first. Products or services mentioned in this video are not a recommendation.

Audio Copyright Disclaimer:

Dr. Daniel Ives, Ph.D. — Founder and CEO — Shift Bioscience Ltd. — Driver Clocks And Longevity

Driver Clocks And Longevity — Dissecting True Functional “Drivers” Of Aging Phenotypes — Dr. Daniel Ives Ph.D., Founder and CEO — Shift Bioscience Ltd.


Dr. Daniel Ives, Ph.D. is Founder and CEO of Shift Bioscience Ltd. (https://shiftbioscience.com), a biotech company making drugs for cellular rejuvenation in humans through the application of machine-learning ‘driver’ clocks to cellular reprogramming, and is the scientific founder who first discovered the gene shifting targets upon which the Shift drug discovery platform is based.

Dr. Ives graduated from Imperial College with a degree in biochemistry and gained his PhD in 2013 working at the MRC Mitochondrial Biology Unit in Cambridge. He carried out his post-doctoral studies under Ian Holt at the National Institute of Medical Research in Mill Hill, now part of the Crick Institute, pursuing damage-removal strategies for mitochondrial DNA mutations.

In 2016 Dr. Ives left the Crick Institute and founded Shift Bioscience to commercialize mitochondrial targeted drugs for age linked diseases, incorporating novel ageing biomarkers technologies, CRISPR screens, and other tools to dissect true functional ‘drivers’ of ageing phenotypes.

A sterile solution: How Crispr could protect wild salmon

Upon an otherwise unruly landscape of choppy sea and craggy peaks, the salmon farms that dot many of Norway’s remote fjords impose a neat geometry. The circular pens are placid on the surface, but hold thousands of churning fish, separated by only a net from their wild counterparts. And that is precisely the conundrum. Although the pens help ensure the salmon’s welfare by mimicking the fish’s natural habitat, they also sometimes allow fish to escape, a problem for both the farm and the environment.

In an attempt to prevent escaped fish from interbreeding with their wild counterparts and threatening the latter’s genetic diversity, molecular biologist Anna Wargelius and her team at the Institute of Marine Research in Norway have spent years working on ways to induce sterility in Atlantic salmon. Farmed salmon that cannot reproduce, after all, pose no threat to the gene pool of wild stocks, and Wargelius has successfully developed a technique that uses the gene-editing technology Crispr to prevent the development of the cells that would otherwise generate functioning sex organs.

In fact, Wargelius’ team was a little too successful. To be financially viable, commercial fish farms need at least some of their stock to reproduce. So the scientists went a step further, developing a method of temporarily reversing the modification they had already made. They’ve created what they call “sterile parents.”

Machine Learning Approach for Predicting Risk of Schizophrenia Using a Blood Test

Summary: Blood tests revealed specific epigenetic biomarkers for schizophrenia. Researchers applied machine learning to analyze the CoRSIVs region of the human genome to identify the schizophrenia biomarkers. Testing the model with an independent data set revealed the AI technology can detect schizophrenia with 80% accuracy.

Source: Baylor College of Medicine.

An innovative strategy that analyzes a region of the genome offers the possibility of early diagnosis of schizophrenia, reports a team led by researchers at Baylor College of Medicine. The strategy applied a machine learning algorithm called SPLS-DA to analyze specific regions of the human genome called CoRSIVs, hoping to reveal epigenetic markers for the condition.

Cracking one more layer of genetic code will finally enable personalized medicine, researcher says

When the Human Genome Project reached its ambitious goal of mapping the entire human genome, it seemed the world was entering an era of personalized medicine, where evidence from our own specific genetic material would guide our care.

That was 2003, and nearly a generation after that spectacular collaborative achievement, we are still waiting for that promise to materialize. We may know that a person carries a gene associated with breast cancer, for example, but not whether that person will go on to develop the disease.

New research by McMaster University evolutionary biologist Rama Singh suggests the reason is that there is another, hidden layer that controls how interact, and how the many billions of possible combinations produce certain results. That layer is composed of largely uncharted biochemical pathways that in cells through chemical reactions.

/* */